Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with "standard" chemotherapy in Kinshasa, Zaire.
about
Understanding pharmacokinetics to improve tuberculosis treatment outcome.AIDS and the lung: update 1995. 2. New developments in the pulmonary diseases affecting HIV infected individuals.Comparison of intermittent ethambutol with rifampicin-based regimens in HIV-infected adults with PTB, Kampala.Impact of HIV infection on tuberculosisAssessing tuberculosis case fatality ratio: a meta-analysis.Tuberculosis control policies in major metropolitan health departments in the United States. VI. Standard of practice in 1996.A review of efficacy studies of 6-month short-course therapy for tuberculosis among patients infected with human immunodeficiency virus: differences in study outcomes.Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection.Tuberculosis in the AIDS eraHIV-associated tuberculosis in developing countries: clinical features, diagnosis, and treatment.Predictors of treatment failure among pulmonary tuberculosis patients in Mulago hospital, UgandaTuberculosis and HIV disease: two decades of a dual epidemic.Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda.Efficacy of an unsupervised 8-month rifampicin-containing regimen for the treatment of pulmonary tuberculosis in HIV-infected adults. Uganda-Case Western Reserve University Research Collaboration.Tuberculosis and HIV interaction in sub-Saharan Africa: impact on patients and programmes; implications for policies.AIDS and the lung: update 1992. 2. Recent developments in the management of the pulmonary complications of HIV disease.Treatment outcome, mortality and their predictors among HIV-associated tuberculosis patients.Measurement and determinants of tuberculosis outcome in Karonga District, MalawiTropical respiratory medicine. 2. Impact of human immunodeficiency virus on tuberculosis in developing countriesTargeted replacement of the mycocerosic acid synthase gene in Mycobacterium bovis BCG produces a mutant that lacks mycosides.An updated systematic review and meta-analysis on the treatment of active tuberculosis in patients with HIV infection.New tuberculosis drug development: targeting the shikimate pathway.Two-year incidence of tuberculosis in cohorts of HIV-infected and uninfected urban Rwandan women.Strong general health care systems: a prerequisite to reach global tuberculosis control targets.Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality.Tuberculosis control policies in major metropolitan health departments in the United States. V. Standard of practice in 1992.Epidemiological Characteristics and Clinical Outcome of HIV-Related Tuberculosis in a Population of TB Patients in South-western Nigeria.Monitoring treatment of patients with pulmonary tuberculosis: can PCR be applied?AJRCCM: 100-Year Anniversary. Focus on Tuberculosis.Tuberculosis at the end of the twentieth century.Serum concentrations of antimycobacterial drugs in patients with pulmonary tuberculosis in Botswana.Cohort profile of a study on outcomes related to tuberculosis and antiretroviral drug concentrations in Uganda: design, methods and patient characteristics of the SOUTH study.Tuberculosis in the UK, 1994: current issues and future trends.Early bactericidal and sterilizing activities of ciprofloxacin in pulmonary tuberculosis.Drug-drug interactions in inmates treated for human immunodeficiency virus and Mycobacterium tuberculosis infection or disease: an institutional tuberculosis outbreak.HIV in Zambia: myth or monster?Emergence during unsuccessful chemotherapy of multiple drug resistance in a strain of Mycobacterium tuberculosis.Risk factors for recurrence of tuberculosis.Comparison between human immunodeficiency virus positive and negative patients with tuberculosis in Southern Brazil.Human immunodeficiency virus and the outcome of treatment for new and recurrent pulmonary tuberculosis in African patients.
P2860
Q30411703-060C5881-2948-42EE-B8C6-4A9C34E485C0Q33604838-7F57EF1B-1EC5-43C2-9028-D7A1A8B10D05Q33847556-1490100B-6200-4E30-89D8-57F0CD595055Q33896460-FD872877-35B2-4D05-820B-0EE9DB505B8DQ33954598-3856EDD3-681A-4EF9-8C7E-4B1DC3ABFC88Q34065515-BAC5F853-2398-437E-BBBB-3DA20CEB9A3AQ34142039-65E2A426-3742-4114-8743-CD2BCE894D6DQ35006626-AC69FD40-7CEC-4A92-9AAD-DAD4FE3973C9Q35365963-B7B9D400-943D-4935-AE27-3B5F485B6916Q35370079-5D8E324C-D606-4B40-8D09-940C346925A5Q35561625-B29D6CA0-184B-461A-82E0-D809832D52A9Q35598500-BF6AEC37-6FB0-42EE-9F4F-BDCBB1AE5A86Q35891202-D08E891C-85B2-47DD-B0CD-F6AF0814C3FCQ36165307-455551CA-45D2-4194-B748-5F3ACA10EF27Q36207851-D2ABB5A8-7474-4495-AE50-868BC4D8337CQ36225746-356B65AB-E9C2-4F0E-A854-73A56C622E43Q36390760-2CA414C8-BBB1-4690-9D63-A6D8F46C35AAQ36551873-3860FE04-4673-4EF6-B8E7-6D8FD7BABC6AQ36566506-2A125736-7C31-4404-9BF5-79B3147632C2Q37604908-5C3D5B44-D418-4A20-81B3-5B7D676FE35DQ38028326-5E75EDB7-06CD-4F49-9A64-60EC4AE3FDCEQ38088794-A02240C8-4300-49D9-AA8F-854F2819CE4EQ38869913-CDED9E2A-4935-4DCB-8EC4-6A0BBD90C9F6Q39204003-5545AD43-239A-4922-8EA3-54D1A2644487Q39312106-80ADABC2-1567-4817-BEC4-113728A8448FQ39404736-3670BE77-3510-4CC5-8DE0-BDDE62C2E871Q39424792-89197163-1EBF-46D0-BD16-A7808BCF33F2Q39453133-274F83CA-310D-4C30-8F62-576303CA940BQ40220575-F7A5D77B-8236-4E5E-B644-6614A6B6060CQ40494905-33FC9E08-2347-4C8D-962E-CA3E4A58F738Q40800121-64816C6A-B5DF-4118-9A68-64179641A3A5Q41996343-78EEEC12-B799-4D8F-8384-B9C65710F7BDQ42415304-DB97BB89-485C-4E45-9E80-A34428B9A770Q43955159-2FAC11C6-47B1-4783-9CE5-C26F2127F18EQ44183258-ECF7A9BE-E6C3-4D34-BDDE-D4DC98281AD4Q44232993-D70502C4-6E9E-44C9-BCC1-94918DAE30CEQ44570155-61DF08F9-260B-4918-83CE-8E43E0BD8CC2Q45208670-F2C8BCBF-3C39-4449-80FB-A12FBED5FC2BQ45749219-213D0A8D-4130-4ED2-99F8-6936CE749D26Q45751006-724D261A-B61C-402E-A572-8150798DCD1C
P2860
Increased mortality and tuberculosis treatment failure rate among human immunodeficiency virus (HIV) seropositive compared with HIV seronegative patients with pulmonary tuberculosis treated with "standard" chemotherapy in Kinshasa, Zaire.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh
1991年學術文章
@zh-hant
name
Increased mortality and tuberc ...... emotherapy in Kinshasa, Zaire.
@en
Increased mortality and tuberc ...... emotherapy in Kinshasa, Zaire.
@nl
type
label
Increased mortality and tuberc ...... emotherapy in Kinshasa, Zaire.
@en
Increased mortality and tuberc ...... emotherapy in Kinshasa, Zaire.
@nl
prefLabel
Increased mortality and tuberc ...... emotherapy in Kinshasa, Zaire.
@en
Increased mortality and tuberc ...... emotherapy in Kinshasa, Zaire.
@nl
P2093
P2860
P921
P356
P1476
Increased mortality and tuberc ...... emotherapy in Kinshasa, Zaire.
@en
P2093
Colebunders RL
Jeugmans J
Karahunga C
Perriëns JH
Willame JC
P2860
P304
P356
10.1164/AJRCCM/144.4.750
P577
1991-10-01T00:00:00Z